

BIO**SIMILARS**



NEDERLAND

**Educational Meeting on
Biosimilar Monoclonal Antibodies**

Amsterdam, 3 september 2015

Welcome

- On behalf of the Initiative Group Biosimilars The Netherlands (IBN)
- On behalf of my co-chairs
- On behalf of the congress organisers

Your chairs today

- Dr. Anton Franken
 - Specialist internal medicine Isala clinics Zwolle
 - Member Dutch Medicines Evaluation Board
- Prof. Dr. Geert D'Haens
 - Gastroenterologist AMC
- Prof. Dr. Arnold G. Vulto
 - Hospital pharmacist & pharmacologist, initiator of Generic & Biosimilar Initiative (GABI) and the IBN.

Initiative Group Biosimilars The Netherlands (IBN)




- Informal platform
- Objective: efficient use of national drug budget.
- Exchange for any kind of info on biosimilars
- Resolve hesitation towards biosimilars
- Sharing knowledge; separate facts from fiction
- Contribute to the public debate
- Participants: healthcare professionals / scientists / professionals from health insurers

Why do we have this meeting?

- Exploding drug budgets €5,86 milliard (2014)
 - Out of hospital: € 4,33 billion (2014; growth ca. 3% / year)
 - In Hospital: € 1,53 billion (2013; growth: 3-5% / year)
- Effective savings options
 - Generic medicines; great success
- Savings options under-utilised:
 - Biosimilars: disappointing uptake

Exhibit 2: Biosimilar penetration of accessible markets



3 generations of biosimilars

- 1st generation
 - Substitution products; immediate effect
 - Epoetin, growth hormone, filgrastim, glargyline insuline
- 2nd generation
 - Distinct pharmacological effect, visible in weeks, but not in every patient
 - TNF-alfa antagonists in reumatoid arthritis and Inflammatory bowel disease
- 3rd generation
 - Offer a chance for an effect at some time in the future (oncology)
 - Bevacizumab, trastuzumab

Where are we now?

- 1st generation
 - Substitution products; immediate effect
 - Epoetin, growth hormone, filgrastim, glargyline insuline
- **2nd generation**
 - ***Distinct pharmacological effect, visible in weeks, but not in every patient***
 - ***TNF-alfa antagonists in RA and IBD***
- 3rd generation
 - Offer a chance for an effect at some time in the future (oncology)
 - Bevacizumab, trastuzumab

Reluctance among prescribers and patients



Some reasons:

- Unfamiliar with biosimilar development model
- Confusing information in the market
- No proper incentives to prescribe biosimilars

An unmet need: educational symposium



- Part i: Technical introductions in biosimilars
- Part II: Experience from Norway with expensive medicines and biosimilars
- Part III: Implementation of biosimilars in The Netherlands

Objectives of the IBN

- Affordable care with uncompromised quality and safety
- Access to proper treatment for all patients
- Sustainable drug provision with room for innovation (adequate price level for generics and biosimilars, so they can survive)
- **This symposium aims to reduce the backlog in knowledge on biosimilars among physicians, policymakers and patients.**



- With this I open the symposium
- I wish you all an inspiring day

- Please, switch of your phones!

